Randomised clinical trial: Improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 5, 2011, Pages 541-550

  Feagan, B G ^a   Sandborn, W J ^b,c   Wolf, D C ^d   Coteur, G ^e   Purcaru, O ^e   Brabant, Y ^e   Rutgeerts, P J ^f  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MAYO CLINIC   (United States)

^d Atlanta Gastroenterology Associates   (United States)

^e UCB   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; INFLIXIMAB;

ABSENTEEISM; ADULT; ARTICLE; CROHN DISEASE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; JOB PERFORMANCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT CROHN DISEASE QUESTIONNAIRE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79251505550     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04568.x     Document Type: Article

References (37)

1. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR,. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003; 98: 2232-8.
2. Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 402-12.
3. Casellas F, Lopez-Vivancos J, Vergara M, Malagelada J,. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 1999; 17: 208-18.
4. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
5. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B,. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005; 11: 909-18.
6. Juan J, Estiarte R, Colome E, Artes M, Jimenez FJ, Alonso J,. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003; 35: 853-61.
7. Blondel-Kucharski F, Chircop C, Marquis P, et al. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001; 96: 2915-20.
8. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 488-96.
9. Irvine EJ,. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999; 28: S23-7.
10. Joshua-Gotlib S, Coyne K, Kimel M, Danilewitz M, Thompson C, Forget S,. Evaluation of the burden of illness in patients with mild to moderate Crohn disease. Drug Benefit Trends 2004; 16: 600-9.
11. Blomqvist P, Ekbom A,. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997; 32: 1134-9.
12. Cohen RD,. IBD indirect costs: the sleeping giant? Gastroenterology 2003; 125: 982-4.
13. Feagan BG, Bala M, Yan S, Olson A, Hanauer S,. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005; 39: 390-5.
14. Lichtenstein GR, Yan S, Bala M, Hanauer S,. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99: 91-6.
15. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-61.
16. Clark IA,. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007; 18: 335-43.
17. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
18. Pache I, Rogler G, Felley C,. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Med Wkly 2009; 139: 278-87.
19. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
21. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
22. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18.
23. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
24. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
25. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
26. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
27. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: 688-95.
28. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
29. Reilly MC, Gerlier L, Brabant Y, Brown M,. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008; 30: 393-404.
30. Reilly MC, Brown M, Brabant Y, Gerlier L, Sandborn WJ,. Defining the minimally important difference of WPAI:CDAI scores: what is a relevant impact on work productivity in active Crohn's disease? Gut 2007; 56 (Suppl. III): Abstract MON-G-355, A159.
31. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ,. Clinical trial: impact of prior infliximab therapy on clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 33: 384-93.
32. Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA,. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment Pharmacol Ther 2009; 30: 757-66.
33. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103: 3132-41.
34. Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S,. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009; 104: 1976-83.
35. Feagan B, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S,. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010; 31: 1276-85.
36. Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN,. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008; 23: 289-96.
37. Coteur G, Feagan B, Keininger DL, Kosinski M,. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment Pharmacol Ther 2009; 29: 1032-41.